Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NR3C2 | P08235 | 5/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.37 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.37 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23763309 | 0.84 | KDM4E (0.44) | KDM4EPOLBSMN1; SMN2NR3C2HRH4 | |
| SCHEMBL14270718 | 0.84 | NOS3 (0.48) | KDM4ENR3C2MAPK14MAPK10HRH4 | |
| SCHEMBL2481330 | 0.82 | RECQL (0.47) | NR3C2MAPK14MAPK10HRH4IGF1R | |
| SCHEMBL17372006 | 0.82 | LOXL2 (0.47) | NR3C2MAPK14MAPK10HRH4IGF1R | |
| Hydrochloric Acid SCHEMBL31330323 | 0.81 | MAPK14 (0.40) | NR3C2MAPK14MAPK10HRH4IGF1R | |
| Hydrochloric Acid SCHEMBL2302210 | 0.78 | IGF1R (0.39) | NR3C2MAPK14MAPK10HRH4IGF1R | |
| SCHEMBL10162013 | 0.77 | NR3C2 (0.54) | NR3C2 | |
| SCHEMBL6560519 | 0.75 | GABRA1 (0.42) | KDM4EPOLBSMN1; SMN2NR3C2GABRA1 | |
| SCHEMBL25522792 | 0.75 | HRH4 (0.39) | NR3C2MAPK14MAPK10HRH4IGF1R | |
| SCHEMBL29851369 | 0.73 | FDPS (0.59) | KDM4EPOLBSMN1; SMN2MAPK14MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11827656-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-03-10 | — | — | US | disclosed |
| US-11225493-B2 | Immunoproteasome inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2022-01-18 | — | — | US | disclosed |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2020-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827656-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | KDM4E 1084/4885POLB 692/4885SMN1; SMN2 1377/4885 |
| US-20200277312-A1 | IMMUNOPROTEASOME INHIBITORS | PSMC2, PSMB7, PSMB2 | KDM4E 1084/4885POLB 692/4885SMN1; SMN2 1377/4885 |
| US-11225493-B2 | Immunoproteasome inhibitors | PSMC2, PSMB7, PSMB2 | KDM4E 1084/4885POLB 692/4885SMN1; SMN2 1377/4885 |
| US-20220073538-A1 | Immunoproteasome Inhibitors | PSMC2, PSMB7, PSMB2 | KDM4E 1084/4885POLB 692/4885SMN1; SMN2 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.